Non-Small-Cell Lung Cancer Market 2025 | Industry Developments, Future Growth, Share & Industry Insights | Sanofi, Novartis AG, Merck & Co Inc, Pfizer Inc, Astrazeneca

Non-Small-Cell Lung Cancer (NSCLC) Market reached USD 25.4 billion in 2022 and is projected to reach USD 47.4 billion by 2031, growing at a CAGR of 8.4% during the forecast period 2024-2031.

DataM Intelligence has published a new research report on "Non Small-Cell Lung Cancer Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/non-small-cell-lung-cancer-market?sg

Key Players: Eli Lilly and Company, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, and Astellas.

Key Development:

United States - Industry Development:

✅ FDA Approves Jazz-Roche Combo for SCLC: On October 2, 2025, the FDA approved a combination of Jazz Pharmaceuticals' Zepzelca and Roche's Tecentriq as the first-line maintenance therapy for extensive-stage small cell lung cancer (SCLC) patients who have not progressed after initial chemotherapy.

✅ Regeneron's Libtayo Expanded Use: On October 8, 2025, the FDA expanded the use of Regeneron's Libtayo as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma, based on a Phase 3 trial showing a 68% reduction in recurrence or death risk.

✅ Merck Acquires Verona Pharma: On July 10, 2025, Merck announced the acquisition of Verona Pharma for approximately $10 billion, adding the COPD drug Ohtuvayre to its pipeline and strengthening its respiratory portfolio.

✅ Bristol-Myers Squibb Acquires Mirati Therapeutics: On June 17, 2025, Bristol-Myers Squibb acquired Mirati Therapeutics for $5.8 billion, gaining access to Krazati, a KRAS inhibitor for NSCLC.

Japan - Industry Development:

✅ Novocure's Optune Lua Approved: On September 17, 2025, Japan's Ministry of Health approved Novocure's Optune Lua for use in combination with PD-1/PD-L1 inhibitors in patients with advanced NSCLC who have progressed after platinum-based chemotherapy.

✅ Takeda's Alunbrig Approved: On January 22, 2021, Japan granted marketing approval to Takeda's Alunbrig for treating ALK fusion gene-positive unresectable advanced or recurrent NSCLC.

South Korea - Industry Development:

✅ Biond Biologics Initiates Phase 2 Study: On October 9, 2025, Biond Biologics announced the initiation of a Phase 2 study of BND-22 in combination with anti-PD-1 therapy for NSCLC and colorectal cancer.

✅ South Korea's Biopharma Innovation: As of March 4, 2025, South Korea ranks third globally in new drug discoveries, with over 1,300 new drug candidates developed in the past three years, many targeting oncology indications.

Europe - Industry Development:

✅ AstraZeneca Acquires EsoBiotec: On March 17, 2025, AstraZeneca acquired Belgian biotech firm EsoBiotec for up to $1 billion, focusing on in-vivo CAR-T cell therapies for cancer and autoimmune diseases.

✅ Daiichi Sankyo's I-DXd Receives FDA Breakthrough Therapy Designation: On August 18, 2025, the FDA granted breakthrough therapy designation to Daiichi Sankyo's ifinatamab deruxtecan (I-DXd) for extensive-stage small cell lung cancer after platinum-based chemotherapy.

Growth Forecast Projected:

The Global Non Small-Cell Lung Cancer Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Non Small-Cell Lung Cancer Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=non-small-cell-lung-cancer-market?sg

Key Segments:

By Drug Class(Epidermal Growth Factor Receptor (EGFR) Inhibitors, Anaplastic Lymphoma Kinase (ALK) Inhibitors, ROS1 Inhibitors, BRAF Inhibitors, Others)

By Type(Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Others)

By Treatment(Chemotherapy, Targeted Therapy, Immunotherapy)

By End-user(Hospitals, Homecare, Specialty Clinics, Others)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Non Small-Cell Lung Cancer producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Non Small-Cell Lung Cancer revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/non-small-cell-lung-cancer-market?sg

FAQ's

Q1: What is the current size of the Non Small-Cell Lung Cancer Market?

A: The Non Small-Cell Lung Cancer Market stood at USD 25.4 billion in 2022 and is set to experience remarkable growth, reaching USD 47.4 billion by 2031 as organizations increasingly prioritize cloud-based security solutions.

Q2: How fast is the Non Small-Cell Lung Cancer Market growing?

A: The Non Small-Cell Lung Cancer Market is on an impressive growth trajectory, expected to expand at a CAGR of 8.4% from 2024-2031

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.